Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis

• Published in: Osteoporosis international Vol. 33; no. 3; pp. 737 - 744
• Main Authors: Schini, M., Peel, N., Toronjo-Urquiza, L., Thomas, E., Salam, S., Khwaja, A., Eastell, R., Walsh, J. S.
• Format: Journal Article
• Language: English
• Published: London Springer London 01-03-2022; Springer Nature B.V
• Subjects: Acute Kidney Injury - chemically induced; Creatinine; Endocrinology; Epidermal growth factor receptors; Glomerular Filtration Rate; Hemodialysis; Humans; Kidneys; Medicine; Medicine & Public Health; Original Article; Orthopedics; Osteoporosis; Osteoporosis - drug therapy; Patients; Renal function; Rheumatology; Zoledronic Acid; United Kingdom > UK; Zoledronic acid; Osteoporosis; Bisphosphonate; Zoledronate; Acute kidney injury; Kidney
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-021-06160-6

Summary
Zoledronate could be contributing to the development of acute kidney injury in a small number of patients. Since estimated glomerular function (eGFR) is simpler to obtain and at least as good a predictor as creatinine clearance (CrCl), it should be used in everyday practice.
Introduction
Zoledronate is widely used for the treatment of osteoporosis. A potential side effect is acute kidney injury (AKI). Advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2019 stated that CrCl and not estimated glomerular filtration rate (eGFR) should be used and that treatment should not be given if CrCl < 35 ml/min. The objective of this study was to compare our current method of assessing renal function (eGFR) with the method proposed by the MHRA (CrCl) for predicting AKI after zoledronate infusions.
Methods
The evaluation was performed at the Metabolic Bone Centre in Sheffield Teaching Hospitals, UK. Data on all the patients who had zoledronate from 1/09/2015 to 1/10/2020 were included.
Results
Data on 4405 patients were retrieved (total number of infusions 7660). Creatinine in the 14 days post-infusion was available for a total of 969 infusions and AKI was observed within 14 days following 45 infusions (4.6%). One patient died due to pneumonia. One patient needed continued haemodialysis. Severe AKI (threefold in creatinine and/or eGFR < 15 ml/min/173 m
2
) was observed within 1 year following 24 infusions. If the MHRA recommendations had been followed, 996 infusions with baseline CrCl < 35 ml/min would not have been given. Of these, follow-up data on serum creatinine within 14 days were available for 142 infusions, showing AKI in only four (2.8%). Logistic regression showed that both CrCl and eGFR were significant factors in predicting AKI within 14 days, but that the current recommended cut-off of CrCl 35 ml/min had poor sensitivity.
Conclusion
Since eGFR is at least as good a predictor of AKI as CrCl, and permits the treatment of more patients at high fracture risk, we recommend that eGFR is used to determine renal function for zoledronate treatment. We suggest that the infusion is given over 30 min in patients with eGFR < 50 ml/min/1.73 m
2
.